Nautilus Biotechnology Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
155
- Stock Symbol
-
NAUT
- Investments
-
1
- Share Price
-
$0.71
- (As of Thursday Closing)
Nautilus Biotechnology General Information
Description
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Contact Information
Website
www.nautilus.bioCorporate Office
- 2701 Eastlake Avenue East
- Seattle, WA 98102
- United States
Corporate Office
- 2701 Eastlake Avenue East
- Seattle, WA 98102
- United States
Nautilus Biotechnology Timeline
Nautilus Biotechnology Stock Performance
As of 24-Apr-2025, Nautilus Biotechnology’s stock price is $0.71. Its current market cap is $89.9M with 126M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.71 | $0.74 | $0.66 - $3.09 | $89.9M | 126M | 144K | -$0.56 |
Nautilus Biotechnology Financials Summary
As of 31-Dec-2024, Nautilus Biotechnology has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 101,905 | 101,905 | 226,003 | (4,301) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (75,207) | (75,207) | (70,520) | (60,324) |
| Net Income | (70,780) | (70,780) | (63,675) | (57,924) |
| Total Assets | 242,743 | 242,743 | 305,565 | 350,052 |
| Total Debt | 30,478 | 30,478 | 34,628 | 30,328 |
Nautilus Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nautilus Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Nautilus Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nautilus Biotechnology Patents
Nautilus Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230287480-A1 | Analyte detection systems and methods of use | Pending | 10-Mar-2022 | ||
| US-20230070896-A1 | Characterization and localization of protein modifications | Pending | 09-Sep-2021 | ||
| US-20220236282-A1 | Systems and methods for biomolecule quantitation | Active | 20-Jan-2021 | ||
| US-12092642-B2 | Systems and methods for biomolecule quantitation | Active | 20-Jan-2021 | ||
| US-20220204549-A1 | Methods of generating nanoarrays and microarrays | Active | 04-Apr-2018 | G01N33/54353 |
Nautilus Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nautilus Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Nautilus Biotechnology Acquisitions (1)
Nautilus Biotechnology’s most recent deal was a Merger/Acquisition with ARYA Sciences Acquisition III for . The deal was made on 09-Jun-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ARYA Sciences Acquisition III | 09-Jun-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Nautilus Biotechnology ESG
Risk Overview
Risk Rating
Updated May, 09, 2023
25.68 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Nautilus Biotechnology FAQs
-
When was Nautilus Biotechnology founded?
Nautilus Biotechnology was founded in 2016.
-
Where is Nautilus Biotechnology headquartered?
Nautilus Biotechnology is headquartered in Seattle, WA.
-
What is the size of Nautilus Biotechnology?
Nautilus Biotechnology has 155 total employees.
-
What industry is Nautilus Biotechnology in?
Nautilus Biotechnology’s primary industry is Biotechnology.
-
Is Nautilus Biotechnology a private or public company?
Nautilus Biotechnology is a Public company.
-
What is Nautilus Biotechnology’s stock symbol?
The ticker symbol for Nautilus Biotechnology is NAUT.
-
What is the current stock price of Nautilus Biotechnology?
As of 24-Apr-2025 the stock price of Nautilus Biotechnology is $0.71.
-
What is the current market cap of Nautilus Biotechnology?
The current market capitalization of Nautilus Biotechnology is $89.9M.
-
What is Nautilus Biotechnology’s annual earnings per share (EPS)?
Nautilus Biotechnology’s EPS for 12 months was -$0.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
